Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH2101 dose-regimen study in multiple myeloma after first-line therapy
2009-012136-33Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IPH 2101 in multiple myeloma (MM) (2 arms), sponsored by Innate Pharma. Started May 2009; status: completed.
02
Drugs
IPH 2101
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-012136-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012136-33.